2 results match your criteria: "B. R. Singh Hospital (Eastern Railway)[Affiliation]"
Interrelation of the Risk Factors of NAFLD at various Stages of Progression of the glycemic Status on long-term Follow-up.
J Assoc Physicians India
June 2022
Trainee for Diplomate of National Board, Department of Medicine, B. R. Singh Hospital (Eastern Railway), Kolkata, West Bengal, India.
Background: Though the risk factors for nonalcoholic fatty liver disease (NAFLD) are the same in diabetic and nondiabetic patients, their exact interrelation and weightage in the pathogenesis are unclear Methods: A total of 130 nondiabetic and 170 diabetic patients with NAFLD [diagnosed on abdominal ultrasound and severity assessed by NAFLD fibrosis score (NFS)] were recruited from 2009 to 2018 and their baseline risk factors [body mass index (BMI), waist circumference (WC), blood pressure, presence of the metabolic syndrome (MS) and insulin resistance (IR) by Homeostasis Model of Assessment for Insulin Resistance (HOMA-IR), fasting blood glucose (FBG) and lipid levels, and hemoglobin A1c (HbA1c) levels] were noted and their interrelationship studied. The nondiabetic patients were prospectively followed up for alteration of glycemic status.
Results: There was presence of high BMI (>23) in 66%, central obesity in 86% (of whom 59% had normal body weight), low high-density lipoprotein cholesterol (HDL) in 51%, high triglyceride (TG) in 68%, high low-density lipoprotein cholesterol (LDL) in 46.
Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India.
Trop Gastroenterol
May 2008
Gastroenterology Unit, Department of Medicine, Central, (B.R. Singh) Hospital Eastern Railway, Sealdah, Kolkata 700 014, West Bengal.
Article Synopsis
- The study aimed to evaluate how well pegylated interferon alpha 2b and ribavirin treatment worked and how well it was tolerated in patients with chronic hepatitis C.
- An open-label trial involved 16 patients receiving either 24 or 48 weeks of therapy, with the primary focus on achieving sustained viral response, while adjusting doses for side effects.
- Results showed a 75% rate of both initial and sustained viral response, but relapses were noted, especially in younger genotype 3 patients; overall, the treatment was safe and effective even for those who had not previously responded to therapy.